M D Chirlaque1,2, D Salmerón3,4, J Galceran5, A Ameijide5, A Mateos6, A Torrella7, R Jiménez8, N Larrañaga4,9, R Marcos-Gragera10, E Ardanaz4,11, M Sant12, P Minicozzi12, C Navarro3,4, M J Sánchez4,13. 1. Department of Epidemiology, Regional Health Authority, IMIB-Arrixaca, Murcia University, Ronda de Levante, 11, 30008, Murcia, Spain. mdolores.chirlaque@carm.es. 2. CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain. mdolores.chirlaque@carm.es. 3. Department of Epidemiology, Regional Health Authority, IMIB-Arrixaca, Murcia University, Ronda de Levante, 11, 30008, Murcia, Spain. 4. CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain. 5. Tarragona Cancer Registry, Foundation Society for Cancer Research and Prevention, Pere Virgili Health Research Institute, Reus, Spain. 6. Albacete Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain. 7. Castellón Cancer Registry, Public Health Directorate, Valencian Government, Castellón, Spain. 8. Cuenca Cancer Registry, Health and Social Welfare Authority, Castile-La Mancha, Spain. 9. Basque Country Cancer Registry, Basque Country Regional Authority, Vitoria-Gasteiz, Spain. 10. Epidemiology Unit and Girona Cancer Registry (UERCG), Oncology Coordination Plan, Department of Health, Autonomous Government of Catalonia, Catalan Institute of Oncology (ICO), Girona Biomedical Institute (IDIBGI), University of Girona, Girona, Spain. 11. Navarre Cancer Registry, Navarre Public Health Institute, Pamplona, Spain. 12. Analytical Epidemiology and Health Impact Unit, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 13. Granada Cancer Registry, Andalusian School of Public Health, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
Abstract
INTRODUCTION: With the aim of providing cancer control indicators, this work presents cancer survival in adult (≥15 years) patients in Spain diagnosed during the period 2000-2007 from Spanish cancer registries participating in the EUROCARE project. METHODS: Cancer cases from nine Spanish population-based cancer registries were included and analysed as a whole. All primary malignant neoplasms diagnosed in adult patients were eligible for the analysis. Cancer patients were followed until 31 December 2008. For each type of cancer, 1-, 3- and 5-year observed and relative survival were estimated by sex, age and years from diagnosis. Furthermore, age-standardized 5-year relative survival for the period 2000-2007 has been compared with that of the period 1995-1999. RESULTS: Skin melanoma (84.6 95% CI 83.0-86.2), prostate (84.6% 95% CI 83.6-85.6) and thyroid (84.2% CI 95% 82.0-86.6) cancers showed the highest 5-year relative survival, whereas the worst prognosis was observed in pancreatic (6% 95% CI 5.1-7.0) and oesophageal (9.4% 95% CI 7.9-11.1) cancers. Overall, survival is higher in women (58.0%) than in men (48.9%). The absolute difference in relative survival between 2000-2007 and 1995-1999 was positive for all cancers as a whole (+4.8% in men, +1.6% in women) and for most types of tumours. Survival increased significantly for chronic myeloid leukaemia, non-Hodgkin's lymphoma and rectum cancer in both sexes, and for acute lymphoid leukaemia, prostate, liver and colon cancers in men and Hodgkin's lymphoma and breast cancer in women. Survival patterns by age were similar in Europe and Spain. A decline in survival by age was observed in all tumours, being more pronounced for ovarian, corpus uteri, prostate and urinary bladder and less for head and neck and rectum cancers. CONCLUSION: High variability and differences have been observed in survival among adults in Spain according to the type of cancer diagnosed, from above 84% to below 10%, reflecting high heterogeneity. The differences in prognosis by age, sex and period of diagnosis reveal opportunities for improving cancer care in Spain.
INTRODUCTION: With the aim of providing cancer control indicators, this work presents cancer survival in adult (≥15 years) patients in Spain diagnosed during the period 2000-2007 from Spanish cancer registries participating in the EUROCARE project. METHODS:Cancer cases from nine Spanish population-based cancer registries were included and analysed as a whole. All primary malignant neoplasms diagnosed in adult patients were eligible for the analysis. Cancerpatients were followed until 31 December 2008. For each type of cancer, 1-, 3- and 5-year observed and relative survival were estimated by sex, age and years from diagnosis. Furthermore, age-standardized 5-year relative survival for the period 2000-2007 has been compared with that of the period 1995-1999. RESULTS:Skin melanoma (84.6 95% CI 83.0-86.2), prostate (84.6% 95% CI 83.6-85.6) and thyroid (84.2% CI 95% 82.0-86.6) cancers showed the highest 5-year relative survival, whereas the worst prognosis was observed in pancreatic (6% 95% CI 5.1-7.0) and oesophageal (9.4% 95% CI 7.9-11.1) cancers. Overall, survival is higher in women (58.0%) than in men (48.9%). The absolute difference in relative survival between 2000-2007 and 1995-1999 was positive for all cancers as a whole (+4.8% in men, +1.6% in women) and for most types of tumours. Survival increased significantly for chronic myeloid leukaemia, non-Hodgkin's lymphoma and rectum cancer in both sexes, and for acute lymphoid leukaemia, prostate, liver and colon cancers in men and Hodgkin's lymphoma and breast cancer in women. Survival patterns by age were similar in Europe and Spain. A decline in survival by age was observed in all tumours, being more pronounced for ovarian, corpus uteri, prostate and urinary bladder and less for head and neck and rectum cancers. CONCLUSION: High variability and differences have been observed in survival among adults in Spain according to the type of cancer diagnosed, from above 84% to below 10%, reflecting high heterogeneity. The differences in prognosis by age, sex and period of diagnosis reveal opportunities for improving cancer care in Spain.
Entities:
Keywords:
Cancer; Cancer registries; Population-based; Prognosis; Spain; Survival
Authors: Roberta De Angelis; Pamela Minicozzi; Milena Sant; Luigino Dal Maso; David H Brewster; Gemma Osca-Gelis; Otto Visser; Marc Maynadié; Rafael Marcos-Gragera; Xavier Troussard; Dominic Agius; Paolo Roazzi; Elisabetta Meneghini; Alain Monnereau Journal: Eur J Cancer Date: 2015-09-26 Impact factor: 9.162
Authors: Gemma Gatta; Laura Botta; María José Sánchez; Lesley Ann Anderson; Daniela Pierannunzio; Lisa Licitra Journal: Eur J Cancer Date: 2015-09-26 Impact factor: 9.162
Authors: Otto Visser; Eva Ardanaz; Laura Botta; Milena Sant; Andrea Tavilla; Pamela Minicozzi Journal: Eur J Cancer Date: 2015-09-26 Impact factor: 9.162
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Sung Hoon Jeong; Jae Hong Joo; Minah Park; Choa Yun; Soo Hyun Kang; Eun-Cheol Park; Yoon Dae Han; Sung-In Jang Journal: Support Care Cancer Date: 2022-09-03 Impact factor: 3.359
Authors: M Rodríguez-Barranco; E Salamanca-Fernández; M L Fajardo; E Bayo; Y-L Chang-Chan; J Expósito; C García; J Tallón; P Minicozzi; M Sant; D Petrova; M A Luque-Fernandez; M-J Sánchez Journal: Clin Transl Oncol Date: 2018-10-19 Impact factor: 3.405
Authors: Elena Salamanca-Fernández; Miguel Rodriguez-Barranco; Yoe-Ling Chang-Chan; Daniel Redondo-Sánchez; Santiago Domínguez-López; Eloísa Bayo; Dariusz Narankiewicz; José Expósito; María José Sánchez Journal: Endocrine Date: 2018-07-24 Impact factor: 3.633
Authors: Inés Gómez-Acebo; Trinidad Dierssen-Sotos; Camilo Palazuelos-Calderón; Beatriz Pérez-Gómez; Pilar Amiano; Marcela Guevara; Antonio J Molina; Laia Domingo; María Fernández-Ortiz; Victor Moreno; Juan Alguacil; Guillermo Fernández-Tardón; Josefa Ibáñez; Rafael Marcos-Gragera; Marian Diaz-Santos; M Henar Alonso; Jessica Alonso-Molero; Gemma Castaño-Vinyals; Andrés García Palomo; Eva Ardanaz; Amaia Molinuevo; Nuria Aragonés; Manolis Kogevinas; Marina Pollán; Javier Llorca Journal: Breast Cancer Res Treat Date: 2020-04-30 Impact factor: 4.872
Authors: R Clèries; A Ameijide; M Buxó; J M Martínez; R Marcos-Gragera; M-L Vilardell; M Carulla; Y Yasui; M Vilardell; J A Espinàs; J M Borràs; J Galceran; À Izquierdo Journal: Clin Transl Oncol Date: 2018-03-06 Impact factor: 3.405
Authors: Adelaida García-Velasco; Lluís Zacarías-Pons; Helena Teixidor; Marc Valeros; Raquel Liñan; M Carmen Carmona-Garcia; Montse Puigdemont; Walter Carbajal; Raquel Guardeño; Núria Malats; Eric Duell; Rafael Marcos-Gragera Journal: Int J Environ Res Public Health Date: 2020-12-19 Impact factor: 3.390